The cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) ribociclib, abemaciclib, and palbociclib have transformed outcomes in patients with ER+ /HER2 − advanced breast cancer (BC). Here, ESR1 is linked to breast carcinoma.